NCT00558181View on ClinicalTrials.gov

High-dose Methylprednisolone and Rituximab in High Risk B-CLL

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

December 31, 2009

Conditions
Chronic B-Lymphocytic Leukemia
Interventions
DRUG

rituximab, methylprednisolone

Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.

Trial Locations (2)

92288

Klaipeda Seamen's Hospital, Klaipėda

08661

Vilnius University Hospital Santariskiu Clinics, Vilnius

All Listed Sponsors
lead

Vilnius University

OTHER

NCT00558181 - High-dose Methylprednisolone and Rituximab in High Risk B-CLL | Biotech Hunter | Biotech Hunter